The invention belongs to the technical field of medicines, and particularly relates to application of a
clinopodium chinense extract in preparation of a
medicine for preventing or treating a non-
alcoholic fatty liver disease. Wherein the calamint is subjected to crushing,
alcohol extraction and reduced pressure
recovery to obtain a concentrate, the concentrate is extracted by
petroleum ether and
ethyl acetate to obtain an
ethyl acetate extract, and the
ethyl acetate extract is purified by
macroporous resin to obtain the calamint extract. The extract obviously inhibits the accumulation of HepG2
cell lipid induced by
palmitic acid, increases PPARalpha and CPT1A, reduces the
protein expression of SREBP-1c, FASN and CD36, and inhibits the
oxidative stress of liver cells. The extract can also obviously relieve
lipid accumulation of NAFLD mice induced by
high fat diet, improve
oxidation resistance and relieve
liver injury. The extract inhibits the activity of alpha-
glucosidase and increases the expression of an
adiponectin receptor 2. It is shown that the
clinopodium megalanthum extract can effectively reduce blood fat, relieve
liver lipid accumulation and inhibit
oxidative stress, has the effects of inhibiting
sugar absorption and protecting liver cells, and can be used for relieving the development of NAFLD.